Related Experiment Videos
Prophylactic versus selective use of surfactant for preventing morbidity and mortality in preterm infants
1Department of Pediatrics, University of Vermont College of Medicine, A-121 Medical Alumni Building, Burlington, Vermont 05405-0068, USA. rsoll@salus.med.uvm.edu
Insights
Prophylactic surfactant administration significantly reduces respiratory distress syndrome in premature infants. This approach lowers the incidence of pneumothorax, pulmonary interstitial emphysema, and mortality, improving overall clinical outcomes.
Area of Science:
- Neonatal Medicine
- Respiratory Physiology
- Pediatric Critical Care
Background:
- Respiratory distress syndrome (RDS) is a common and serious condition in premature infants.
- Surfactant replacement therapy is a cornerstone in managing established RDS.
- The optimal timing for surfactant administration (prophylactic vs. rescue) remains a key clinical question.
Purpose of the Study:
- To compare the efficacy of prophylactic surfactant administration versus surfactant treatment for established RDS in premature infants.
- To evaluate the impact on clinical outcomes and adverse events.
Main Methods:
- Systematic review and meta-analysis of randomized controlled trials (RCTs).
- Searches included major databases (Oxford Database of Perinatal Trials, Medline) and grey literature.
- Data extraction focused on clinical outcomes such as pneumothorax, intraventricular hemorrhage, bronchopulmonary dysplasia, and mortality.
Main Results:
- Prophylactic surfactant administration demonstrated an initial improvement in respiratory status.
- Meta-analysis confirmed a significant decrease in the incidence of pneumothorax, pulmonary interstitial emphysema, and mortality.
- No significant adverse effects were associated with prophylactic surfactant administration.
Conclusions:
- Prophylactic surfactant administration improves clinical outcomes for at-risk premature infants (e.g., <30-32 weeks gestation).
- Key benefits include reduced rates of pneumothorax, pulmonary interstitial emphysema, and mortality.
- Further research is needed to define precise criteria for identifying infants who would benefit most from prophylactic surfactant.
Background:
This section is under preparation and will be included in the next issue.
Objectives:
To compare the effect of prophylactic surfactant administration to surfactant treatment of established respiratory distress syndrome in premature infants.
Search Strategy:
Searches were made of the Oxford Database of Perinatal Trials, Medline (MeSH terms: pulmonary surfactant; limits: age groups, newborn infants), previous reviews including cross-references, abstracts, conference and symposia proceedings, expert informants, and journal handsearching in the English language.
Selection Criteria:
Randomized controlled trials which compared the effects of prophylactic surfactant administration to surfactant treatment of established respiratory distress syndrome in premature infants were included in the analysis.
Data Collection And Analysis:
Data regarding clinical outcomes including the incidence of pneumothorax, pulmonary interstitial emphysema, patent ductus arteriosus, necrotizing enterocolitis, intraventricular hemorrhage (any grade and severe intraventricular hemorrhage), bronchopulmonary dysplasia, mortality, bronchopulmonary dysplasia or death, and retinopathy of prematurity were excerpted from the reports of the clinical trials by the reviewers. Data analysis was done in accordance with the standards of the Cochrane Neonatal Review Group.
Main Results:
The majority of included studies noted an initial improvement in the respiratory status and a decrease in the incidence of respiratory distress syndrome in infants who received prophylactic surfactant. The meta-analysis supports a decrease in the incidence of pneumothorax, a decrease in the incidence of pulmonary interstitial emphysema, a decrease in the incidence of mortality and a decrease in the incidence of bronchopulmonary dysplasia or death associated with prophylactic administration of surfactant. No significant untoward effects of prophylactic surfactant administration are noted.
Reviewer'S Conclusions:
Prophylactic surfactant administration to infants judged to be at risk of developing respiratory distress syndrome (intubated infants less than 30-32 weeks gestation) has been demonstrated to improve clinical outcome. Infants who receive prophylactic surfactant have a decreased incidence of pneumothorax, a decreased incidence of pulmonary interstitial emphysema and a decreased incidence of mortality. However, it remains unclear exactly which criteria should be used to judge "at risk" infants who would require prophylactic surfactant administration.